Tae Won Kim

Quick facts

Phase 2 pipeline

• Aatezolizumab plus Bevacizumab · Oncology
  Atezolizumab blocks PD-L1 to enhance immune response while bevacizumab inhibits VEGF to reduce tumor angiogenesis, combining immunotherapy with anti-angiogenic therapy.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Tae Won Kim portfolio CI brief
• Tae Won Kim pipeline updates RSS